Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
04/23/2014
Trade Name:
Kuvan
Generic Name or Proper Name (*):
sapropterin dihydrochloride
Indications Studied:
Treatment to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU)
Label Changes Summary:
Expanded indication to include 1 month to 4 years; previously approved for use in 4 years and older Safety and effectiveness have not been established in neonates Adversereactions observed in pediatric patients 1 month – 6 years were similar to adults except for an increased incidence of low Phe levels. 25% (16/65) experienced low Phe for age Information on adding crushed tablet or powder for oral solution to small amounts of soft food such as apple sauce Information on dosing, adverse reactions, PK parameters, and clinical trials
BPCA(B):
B
Sponsor:
BioMarin Pharmaceutical Inc.
Pediatric Exclusivity Granted Date:
03/13/2014
NNPS:
FALSE
-
-